Diplomat, the largest independent specialty pharmacy, has been selected as a provider of Zydelig tablets. Zydelig was approved by the US Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers.

“We are pleased to partner with Gilead and be included in the limited panel of distribution for Zydelig,” said Gary Kadlec, R.Ph, president of Diplomat. “Our expertise in working with limited-distribution drugs along with our comprehensive patient care programmes provides the support needed to improve patient compliance, adherence and outcomes.”

Zydelig is indicated for the treatment of relapsed follicular B-Cell non-Hodgkin lymphoma (FL), small lymphocytic lymphoma, and in combination with rituximab for patients with relapsed chronic lymphocytic leukaemia (CLL). Over 200,000 patients in the US are living with FL, SLL or CLL which are slow-growing incurable blood cancers that can lead to life-threatening complications such as anaemia, serious infection and bone marrow failure.

Diplomat’s high-touch approach to patient care achieved a 99 per cent patient satisfaction rating in 2013. The specialty pharmacy’s care programmes include timely prescription delivery, side-effect management support and 24 hour access to patient care coordinators, nurses and pharmacists.